重组人脑利钠肽介导氢氯噻嗪、氯沙坦和美托洛尔治疗充血性心力衰竭的疗效评价
【摘要】 目的 探讨重组人脑利钠肽(rhBNP)介导下治疗充血性心力衰竭(CHF)患者的疗效、安全性及短期预后。方法 86例CHF急性发作期患者随机分为rhBNP组(42例)及常规组(44例), 常规组患者使用氢氯噻嗪、氯沙坦和美托洛尔等常规药物治疗, rhBNP组在常规组的基础上, 静脉注射rhBNP。观察两组治疗前后的临床疗效、血浆N端脑钠肽前体(NT- proBNP)浓度、血肌酐清除率及出院后患者主要心血管事件发生率的差异。结果 与治疗前比较, 两组血浆NT-proBNP 水平均明显降低, 且rhBNP组下降更为显著(P<0.05);基础肾功能异常的CHF患者, 使用rhBNP治疗后, 血肌酐清除率改善程度明显优于使用常规治疗方案的患者(P<0.05)。同时, rhBNP组临床疗效评价总有效率92.86%, 显著高于常规组的总有效率68.18%(P<0.05);治疗后1年内, rhBNP组总心血管不良事件发生率为9.52%, 显著低于常规组34.09%(P<0.01)。结论 rhBNP介导下治疗CHF具有良好的临床疗效, 且可以改善肾功能及降低不良心血管事件的发生率, 安全性较高。
【关键词】 充血性心力衰竭;重组人脑利钠肽;肾功能;疗效
【Abstract】 Objective To investigate the curative effect, safety and short-term prognosis of recombinant human brain natriuretic peptide (rhBNP) guided therapy in the treatment of congestive heart failure (CHF). Methods A total of 86 cases in acute attack stage of CHF were randomly divided into rhBNP group (n=42) and conventional group (n=44). The conventional group received conventional drug treatment, such as hydrochlorothiazide, lorsartan and metoprolol, and the The rhBNP group received additional rhBNP through intravenous injection. The changes of curative effects, concentration of plasma N terminal pro-brain natriuretic peptide (NT-proBNP), clearance rate of serum creatinine and incidences of post-discharge major adverse cardiac event of the two groups were all observed. Results Compared with initial data before treatment, concentrations of plasma NT-proBNP in both two group were signific...
== 试读已结束,如需继续阅读敬请充值会员 ==
|
本站文章均为原创投稿,仅供下载参考,付费用户可查看完整且有格式内容!
(费用标准:38元/2月,98元/2年,微信支付秒开通!) |
升级为会员即可查阅全文 。如需要查阅全文,请 免费注册 或 登录会员 |